Core Insights - Alumis Inc. reported positive Phase 3 topline results for envudeucitinib, showing significant skin clearance and symptom improvement in moderate-to-severe plaque psoriasis, along with a favorable safety profile [1][2] - The company plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026 [1] - Anticipated pivotal Phase 2b clinical data for envudeucitinib in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026 [1][7] - Alumis completed a public offering, raising approximately $345.1 million in gross proceeds in January 2026 [1][5] Phase 3 Clinical Trials - The Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib met all primary and secondary endpoints with high statistical significance [5] - Approximately 65% of patients achieved a Psoriasis Area Severity Index (PASI) 90, and over 40% achieved PASI 100 at Week 24 [5] - The drug demonstrated a favorable safety and tolerability profile consistent with earlier Phase 2 results [5] Financial Performance - For the year ended December 31, 2025, Alumis reported total revenue of $24.05 million, primarily from license and collaboration revenue [15] - Research and development expenses increased to $386.0 million from $265.6 million in 2024, driven by clinical trial costs and increased headcount [12][15] - The net loss for 2025 was $243.3 million, an improvement from a net loss of $294.2 million in 2024 [12][15] Pipeline and Future Plans - Alumis is evaluating additional indications for envudeucitinib beyond psoriasis and SLE, as part of a unified TYK2 franchise development strategy [2][5] - An update on the TYK2 franchise strategy, including the timing for commencing A-005's Phase 2 trial, is expected in the second quarter of 2026 [5][8] - The company plans to present additional Phase 3 data at the American Academy of Dermatology (AAD) Annual Meeting in March 2026 [11]

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] Company Overview - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The company also has lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 10:40 a.m. ET [1] - A live webcast of the event will be available on the Alumis website, with a replay archived for 90 days [2]

Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Event**: Oppenheimer's Annual Healthcare Conference - **Key Speakers**: Martin Babler (CEO), John Schroer (CFO) Core Industry and Product Insights Psoriasis Treatment - **Product**: Envudeucitinib - **Phase 3 Data**: Positive top-line results announced in January - **Primary Endpoint Results**: - PASI 75: Average of 74% - sPGA 0/1: Average of 59% at week 16 [3][4] - **Secondary Results**: - PASI 90: Approximately 65% at week 24 - PASI 100: Just over 40% on average [5] - **Safety Profile**: Consistent with Phase II results; common side effects include headaches, upper respiratory infections, and acne. No malignancy signals observed [6][15][19]. Competitive Landscape - **Competitors**: J&J's IL-23 blocker and Takeda's TYK2 inhibitors - **Market Positioning**: Emphasis on the unique benefits of the TYK2 pathway, including improved patient-reported outcomes and quality of life [7][9]. - **Dosing Preference**: Market research indicates a preference for a twice-daily dosing regimen without food effects over a once-daily regimen with fasting requirements [11][12]. Regulatory and Commercial Plans - **NDA Submission**: Planned for the second half of the year, contingent on 48-week data [25]. - **Commercial Strategy**: Strong plan in place, with considerations for potential partnerships due to the broad indication landscape [26]. Future Opportunities Systemic Lupus Erythematosus (SLE) - **Unmet Need**: High demand for effective oral treatments; current approved drugs have low efficacy [27]. - **Ongoing Trial**: Phase 2b trial with over 400 patients, primary endpoint BICLA, results expected in Q3 [28]. - **Execution Strategy**: Focus on patient selection and managing co-medications to minimize placebo rates [30]. Pipeline Developments - **Lonigutamab**: Ongoing evaluation of its mechanism and competitive landscape; potential for CNS indications [39][41]. - **CNS Penetrant TYK2**: Consideration of broader applications beyond CNS [39]. Additional Considerations - **Malignancy Concerns**: No significant malignancy signals observed; background rates of cancer in trials acknowledged [18][21]. - **FDA Guidance**: Recent communications suggest potential for single trial approvals, which could impact SLE trial strategy [35][36]. This summary encapsulates the key points discussed during the conference call, highlighting Alumis's strategic positioning, product developments, and future opportunities in the healthcare market.

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [2] Product Pipeline - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001), aimed at treating systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneously delivered therapy for thyroid eye disease [2] - Several preclinical programs have been identified through the company's precision approach [2] Investor Engagement - Alumis will participate in multiple investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [4] - Live webcasts of these events will be accessible on the company's website, with replays archived for 90 days [1][4]

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [5] Recent Offering - Alumis announced the closing of an upsized underwritten public offering of 20,297,500 shares of common stock at a price of $17.00 per share, resulting in gross proceeds of approximately $345.1 million before deductions [1] - The offering included the full exercise of the underwriters' option to purchase an additional 2,647,500 shares [1] Underwriters - Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities served as joint book-running managers for the offering, while Baird and Oppenheimer & Co. acted as co-lead managers [2] Regulatory Compliance - The public offering was conducted under a shelf registration statement on Form S-3, which was previously filed and declared effective by the SEC on August 19, 2025 [3]

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [5] Public Offering Details - Alumis announced an upsized underwritten public offering of 17,650,000 shares of common stock priced at $17.00 per share, aiming for gross proceeds of approximately $300.0 million [1] - The offering is expected to close on January 9, 2026, subject to customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 2,647,500 shares at the public offering price [2] Pipeline and Product Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [5] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease [5]

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company is leveraging a proprietary data analytics platform and precision approach to develop its pipeline of therapies [5] Public Offering Announcement - Alumis announced plans to commence an underwritten public offering of $175.0 million of its common stock, with an additional option for underwriters to purchase up to $26.25 million of shares [1] - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1] Management of the Offering - Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering [2] Regulatory Compliance - The offering is being made pursuant to a shelf registration statement on Form S-3, which was previously filed and declared effective by the SEC on August 19, 2025 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] Company Overview - Alumis is developing envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also includes A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab for thyroid eye disease [2] - Several preclinical programs are being identified through a precision approach [2] Upcoming Events - Alumis will participate in the Guggenheim's 2nd Annual Healthcare Innovation Conference from November 10-12, 2025, with a fireside chat scheduled for November 11, 2025, at 1:30 pm ET [4] - The company will also present at the Stifel 2025 Healthcare Conference from November 11-13, 2025, on November 12, 2025, at 2:00 pm ET [4]

Summary of Alumis Inc. Conference Call Company Overview - **Company**: Alumis Inc. (Ticker: ALMS) - **Industry**: Precision Immunology - **Key Products**: Focus on TIK2 inhibitors for autoimmune diseases, specifically psoriasis and lupus Core Points and Arguments 1. **Clinical Assets**: Alumis has three clinical assets, with a strong research organization. Currently in Phase 3 for psoriasis and Phase 2b for lupus, with read-outs expected in early Q1 and Q3 of next year respectively [2][3] 2. **TIK2 Target**: TIK2 was selected as a target due to its significant role in autoimmune diseases, with 5% of the population having mutations that provide protection against such diseases [4][5] 3. **Efficacy of Envu**: The company's TIK2 inhibitor, now called Envutucitinib (Envu), has shown a clean safety profile and high efficacy, with PASI-75 scores being the highest seen with an oral drug [8][10] 4. **Market Positioning**: The company believes that the oral drug market is underutilized, with less than 10% of diagnosed psoriasis patients on biologics. There is a strong preference for oral treatments among patients [18][19] 5. **Phase 3 Data Benchmarking**: The company is focused on long-term efficacy data (24-week and 52-week) rather than short-term results, which are more relevant for dermatologists [10][11] 6. **Lupus Opportunity**: The Phase 2b trial for lupus is pivotal, with the potential for only one Phase 3 trial if successful. The genetic evidence supports TIK2's role in lupus treatment [30][32] 7. **Trial Design**: The lupus trial includes 408 patients with strict entry criteria to minimize placebo effects, focusing on active SLE patients [35][36] 8. **Market Expansion**: There is potential to expand the systemic treatment market with better-tolerated oral drugs, targeting patients who may currently be on topical therapies [21][22] 9. **Launch Strategy**: Alumis plans to learn from competitors' launches, focusing on drug positioning, pricing, and effective communication of benefits [22][23] 10. **Cash Position**: As of the end of Q2, Alumis had $486 million in cash, expected to last into 2027, with anticipated spikes in R&D spending due to Phase 3 trial enrollment [46] Additional Important Content - **BMI Considerations**: The company acknowledges that BMI can influence drug efficacy and is a factor in cross-trial comparisons [15][16] - **Formulation Development**: Multiple formulations of Envu are being developed, with plans for a once-daily dosing regimen [28] - **Collaboration Potential**: Alumis is unlikely to launch Envu globally on its own and is considering partnerships for market entry [26][27] - **Future Indications**: The company is exploring the potential of TIK2 inhibitors in other diseases driven by interferon pathways, such as Sjogren's syndrome [33] This summary encapsulates the key points discussed during the conference call, highlighting Alumis Inc.'s strategic focus, clinical developments, and market opportunities in the precision immunology sector.

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] - Upcoming investor conferences will feature Alumis, providing opportunities for engagement with investors [1][4] Company Overview - Alumis is developing therapies aimed at improving health outcomes for patients with immune-mediated diseases, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline includes envudeucitinib (formerly ESK-001) and A-005 for various systemic and neuroinflammatory conditions, as well as lonigutamab for thyroid eye disease [2] - The company has several preclinical programs identified through its precision approach [2] Upcoming Events - Alumis will participate in multiple investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 3 at 9:45 am ET [4] - Wells Fargo 2025 Healthcare Conference on September 5 at 9:30 am ET [4] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 4:50 pm ET [4] - H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 10:30 am ET [4] - Baird 2025 Global Healthcare Conference on September 10 at 2:35 pm ET [4] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET [4]